A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
Open accessPublished version of a preprint
The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index.
Abstract
A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously. Twelve pigs (n = 6/intervention) were euthanized one day post-injection, while the remaining twelve pigs were euthanized seven days post-injection (n = 6/intervention). We performed autoradiography on hippocampus and prefrontal cortex (PFC) sections with [3H]UCB-J (SV2A), [3H]MDL100907 (5-HT2AR antagonist) and [3H]Cimbi-36 (5-HT2AR agonist). One day post psilocybin injection, we observed 4.42% higher hippocampal SV2A density and lowered hippocampal and PFC 5-HT2AR density (−15.21% to −50.19%). These differences were statistically significant in the hippocampus for all radioligands and in the PFC for [3H]Cimbi-36 only. Seven days post-intervention, there was still significantly higher SV2A density in the hippocampus (+9.24%) and the PFC (+6.10%), whereas there were no longer any differences in 5-HT2AR density. Our findings suggest that psilocybin causes increased persistent synaptogenesis and an acute decrease in 5-HT2AR density, which may play a role in psilocybin’s antidepressive effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure A1 Saturation assay of [3H]UCB-J (a), [3H]MDL100907 (b) and [3H]Cimbi-36 (c) in the grey matter of the pig brain.](https://figures.cochat.ai/paper-figures/38d25f421ca64d38a1c3569974548753/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 1 Group-wise comparisons of synaptic vesicle protein 2A (SV2A) density (mean ± SD) in the hippocampus (a) and prefrontal cortex (PFC) (b) as measured with [3H]UCB-J autoradiography.](https://figures.cochat.ai/paper-figures/6f3973e6df5d483a8417e5831679ac65/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 2 Group-wise comparison of 5-HT2AR density (mean ± SD) as measured with [3H]MDL100907 and [3H]Cimbi-36 in the hippocampus (a,c) and PFC (b,d) using autoradiography.](https://figures.cochat.ai/paper-figures/aa078f12462a4e58b83778f85f9b47a1/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psilocybin has also been shown to increase the density of SV2A in vivo as measured by PET imaging (155).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“new imaging tools have the potential to identify biomarkers of psychoplastogen efficacy”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Using [3H]UCB-J in vitro autoradiography, we recently showed that a single administration of the 5-HT2A receptor agonist psilocybin was associated with higher hippocampal SV2A levels in awake pigs 24 h after administration [52].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 2×
“Calibration, quantification and data evaluation was done using ImageJ software (NIH Image, Bethesda, MD, USA) [45].”
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“We investigate brain effects one day after psilocybin administration because the days following a psychedelic experience may provide a therapeutic window to treat mood disorders [6,7].”
InfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“A follow-up seven days after a psilocybin intervention is done because this is when depressive scores have been reported to be the lowest [6].”
InfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 2×
“The increase in synaptic marker SV2A may result from the stimulation of the 5-HT2AR, TrkB and mTOR signalling pathways [10].”
Pompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 881 · cited 1×
“More caution should be exerted when comparing the radioligands in hippocampus because the hippocampus has high levels of 5-HT2CR, with a density similar to 5-HT2AR [34,35] and [3H]Cimbi-36 also has affinity to 5-HT2CR [36,37].”
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808 · cited 1×
“Both post-mortem human brain [14,15] and in vivo[16] studies in depressed individuals have shown a loss of synapses through the down-regulation of synaptic proteins and genes.”
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
KENT, R. S., DE LEAN, A., & LEFKOWITZ, R. J. (1980) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14062-5 · Cited by 553 · cited 1×
“The affinity states of the receptors are considered to represent different functional states of the receptor, high-affinity being functionally active (activation of Gαi1-protein pathway) in contrast to the low-affinity state (activation of canonical Gαq/11-protein pathway) [26].”
BackgroundMadsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 4×
“At the time of euthanasia, blood was drawn for the measurement of plasma psilocin levels, which were measured by ultra-high-performance liquid chromatography coupled to tandem mass spectrometry as previously described [43].”
BackgroundMethodInfluentialSelf-citationLower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484 · cited 2×
“Both post-mortem human brain [14,15] and in vivo[16] studies in depressed individuals have shown a loss of synapses through the down-regulation of synaptic proteins and genes.”
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379 · cited 1×
“active compound psilocin which has a high affinity to 5-HT2AR, but also to other 5-HT receptors such as 5-HT1AR and 5-HT2CR [1,4,5].”
A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System
Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., Svarer, C., Greve, D. N., & Knudsen, G. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2830-16.2016 · Cited by 368 · cited 1×
“It is, however, well known that brain 5-HT2AR mRNA expression does not correlate with 5HT2AR protein content [32].”
Self-citationDuric, V., Banasr, M., Stockmeier, C. A., Simen, A. A., Newton, S. S., Overholser, J. C., Jurjus, G. J., Dieter, L., & Duman, R. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000016 · Cited by 304 · cited 1×
“Both post-mortem human brain [14,15] and in vivo[16] studies in depressed individuals have shown a loss of synapses through the down-regulation of synaptic proteins and genes.”
Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists
Gray, J. A., & Roth, B. L. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00623-2 · Cited by 296
Rapid modulation of spine morphology by the 5-HT 2A serotonin receptor through kalirin-7 signaling
Jones, K. A., Srivastava, D. P., Allen, J. A., Strachan, R. T., Roth, B. L., & Penzes, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905884106 · Cited by 226 · cited 1×
“shown to induce a kalirin-7-dependent increase in dendritic spine size that may play a role in regulating structural plasticity in the cortex [14].”
BackgroundMorales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175
SV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138
Morales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., & Perez-Castillo, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01011-0 · Cited by 138
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131 · cited 1×
“active compound psilocin which has a high affinity to 5-HT2AR, but also to other 5-HT receptors such as 5-HT1AR and 5-HT2CR [1,4,5].”
Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00099 · Cited by 131 · cited 1×
“Together with other markers of neuroplasticity, increased levels of SV2A after intervention with a psychedelic drug adds to the scientific evidence that psychedelics enhance neuroplasticity which may be the mechanism of action of its antidepressant properties [31].”
Berry, S. A., Shah, M. C., Khan, N., & Roth, B. L. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09230-2 · Cited by 110 · cited 1×
“Stimulation of 5-HT2AR leads to rapid receptor internalization [28].”
BackgroundSerotonin2 agonist administration down-regulates rat brain serotonin2 receptors
Buckholtz, N. S., Zhou, D., & Freedman, D. X. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90342-6 · Cited by 108 · cited 1×
“It is already well-known that a transient 5-HT2AR down-regulation occurs upon agonist stimulation, followed by a return to baseline [41].”
Puzzling Out Synaptic Vesicle 2 Family Members Functions
Bartholome, O., Van den Ackerveken, P., Sánchez Gil, J., de la Brassinne Bonardeaux, O., Leprince, P., Franzen, R., & Rogister, B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00148 · Cited by 107 · cited 1×
“Synaptic vesicle protein 2A (SV2A) is an integral 12-transmembrane domain glycoprotein expressed in synaptic vesicles throughout the brain [17], and SV2A density is thought to reflect presynaptic density [18].”
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Quevedo, J. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0451-2 · Cited by 98
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77 · cited 1×
“Synaptic vesicle protein 2A (SV2A) is an integral 12-transmembrane domain glycoprotein expressed in synaptic vesicles throughout the brain [17], and SV2A density is thought to reflect presynaptic density [18].”
Finnema, S. J., Stepanov, V., Ettrup, A., Nakao, R., Amini, N., Svedberg, M., Lehmann, C., Hansen, M., Knudsen, G. M., & Halldin, C. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.035 · Cited by 72 · cited 2×
“More caution should be exerted when comparing the radioligands in hippocampus because the hippocampus has high levels of 5-HT2CR, with a density similar to 5-HT2AR [34,35] and [3H]Cimbi-36 also has affinity to 5-HT2CR [36,37].”
Self-citationEttrup, A., Svarer, C., McMahon, B., da Cunha-Bang, S., Lehel, S., Møller, K., Dyssegaard, A., Ganz, M., Beliveau, V., Jørgensen, L. M., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.02.001 · Cited by 72 · cited 1×
“The fraction of functional 5-HT2AR has to some extent been assessed in vivo in non-human primates [37] and humans [38] using [11C]Cimbi-36 as an agonist and [11C]MDL100907 or [18F]altanserin as antagonist radioligands, but a more precise estimate is difficult in vivo because of missing information about the free fract…”
Self-citationGarcía‐Bea, A., Miranda-Azpiazu, P., Muguruza, C., Marmolejo-Martínez-Artesero, S., Díez-Alarcia, R., Gabilondo, A. M., Callado, L. F., Morentín, B., González‐Maeso, J., & Meana, J. J. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.10.013 · Cited by 59
Donovan, L. L., Johansen, J. V., Ros, N. F., Jaberi, E., Línnet, K., Johansen, S. S., Ozenne, B., Issazadeh‐Navikas, S., Hansen, H. D., & Knudsen, G. M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.013 · Cited by 50 · cited 6×
“[30] identified which dose of psilocybin to give to make it comparable to a dose that elicits psychedelic effects in humans.”
BackgroundMethodInfluentialSelf-citationLópez-Giménez, J. F., Villazón, M., Brea, J., Loza, M. I., Palacios, J. M., Mengod, G., & Vilaró, M. T. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12295-x · Cited by 47
Distribution and characterization of [3H]mesulergine binding in human brain postmortem
Marazziti, D., Rossi, A., Giannaccini, G., Zavaglia, K. M., Dell’Osso, L., Lucacchini, A., & Cassano, G. B. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00045-0 · Cited by 44 · cited 1×
“More caution should be exerted when comparing the radioligands in hippocampus because the hippocampus has high levels of 5-HT2CR, with a density similar to 5-HT2AR [34,35] and [3H]Cimbi-36 also has affinity to 5-HT2CR [36,37].”
Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36
Ettrup, A., Holm, S., Hansen, M. A., Wasim, M., Santini, M. A., Palner, M., Madsen, J., Svarer, C., Kristensen, J. L., & Knudsen, G. M. (2013) · Molecular Imaging and Biology · doi:10.1007/s11307-012-0609-4 · Cited by 43 · cited 1×
“More caution should be exerted when comparing the radioligands in hippocampus because the hippocampus has high levels of 5-HT2CR, with a density similar to 5-HT2AR [34,35] and [3H]Cimbi-36 also has affinity to 5-HT2CR [36,37].”
Self-citationAnji, A., Kumari, M., Sullivan, N. R., Bryan, G. S., & Hensler, J. G. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00026-5 · Cited by 38 · cited 1×
“Our finding of a transient decrease in 5-HT2AR density, but not mRNA, one day after psilocybin is in line with results for the psychedelic substance DOI, where a significant difference in 5-HT2AR protein expression was not accompanied by a change in mRNA gene expression [33].”
Zhang, M., Radford, K. D., Driscoll, M. Y., Purnomo, S., Kim, J., & Choi, K. H. (2019) · IBRO Reports · doi:10.1016/j.ibror.2019.01.006 · Cited by 36 · cited 1×
“Atypical antidepressants like ketamine are also associated with neuroplastic effects through proteins like cFos, pERK and BDNF in PFC and hippocampus in a social defect stress rodent model [30].”
Menneson, S., Ménicot, S., Ferret‐Bernard, S., Guérin, S., Rome, V., Normand, L. L., Randuineau, G., Gambarota, G., Noirot, V., Etienne, P. L., et al. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00161 · Cited by 36 · cited 1×
“psychosocial chronic-stress pig model [43].”
Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non‐human primate and human brain
Varnäs, K., Stepanov, V., & Halldin, C. (2020) · Synapse · doi:10.1002/syn.22157 · Cited by 25
Development of Homogeneous High-Affinity Agonist Binding Assays for 5-HT 2 Receptor Subtypes
Song, J., Hanniford, D., Doucette, C., Graham, E., Poole, M. F., Ting, A. E., Sherf, B. A., Harrington, J., Brunden, K. R., & Stricker‐Krongrad, A. (2005) · Assay and Drug Development Technologies · doi:10.1089/adt.2005.3.649 · Cited by 24
Shalgunov, V., van Waarde, A., Booij, J., Michel, M. C., Dierckx, R., & Elsinga, P. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21552 · Cited by 24
López‐Giménez, J. F., Vilaró, M. T., Palacios, J. M., & Mengod, G. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3636-8 · Cited by 12
Miranda-Azpiazu, P., Díez-Alarcia, R., García‐Bea, A., González‐Maeso, J., Morentín, B., & Meana, J. J. (2013) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(13)70309-2 · Cited by 3
Cited by
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
The neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 269
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Increased synaptic and dendritic density has been observed at 72 hours post-treatment in multiple studies [27, 37, 39].”
BackgroundResultNeuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Metadata
- Authors
- Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Harvard University (US)
- Corresponding author
- Hansen, Hanne Demant
- Knudsen, Gitte Moos
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 22
- Issue
- 2
- Pages
- 835
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7830000
- OpenAlex
- W3108222140
- Cited by
- 200
- References
- 48
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 40 · 2023: 41 · 2022: 33 · 2021: 17
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Horizon 2020 (813528)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psilocybin, 5-HT2A receptor, synaptic density, synaptogenesis, SV2A, hippocampus, prefrontal cortex, antidepressant mechanism, psychedelics, pig brain, receptor down-regulation
- MeSH terms
- Animals, Antidepressive Agents, Autoradiography, Brain, Female, Hallucinogens, Hippocampus, Ligands, Psilocybin, Swine, Synapses, Prefrontal Cortex, Receptor, Serotonin, 5-HT2A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.